Resources from the same session
451O - Preliminary evidence of clinical activity from phase I and Ib trials of the CLK/DYRK inhibitor cirtuvivint (CIRT) in subjects with advanced solid tumors
Presenter: Aaron Scott
Session: Proffered Paper session: Developmental therapeutics
Resources:
Abstract
Slides
Webcast
452O - A phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2–p53 antagonist BI 907828 in patients (pts) with solid tumours
Presenter: Patrick Schoeffski
Session: Proffered Paper session: Developmental therapeutics
Resources:
Abstract
Slides
Webcast
453O - DS-7300 (B7-H3 DXd antibody-drug conjugate [ADC]) shows durable antitumor activity in advanced solid tumors: Extended follow-up of a phase I/II study
Presenter: Toshihiko Doi
Session: Proffered Paper session: Developmental therapeutics
Resources:
Abstract
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session: Developmental therapeutics
Resources:
Webcast
450O - Initial monotherapy results of a phase I first-in-human study of ULK1/2 inhibitor DCC-3116 alone and in combination with MAPK pathway inhibition
Presenter: Anthony Tolcher
Session: Proffered Paper session: Developmental therapeutics
Resources:
Abstract
Slides
Webcast
454O - A phase (Ph) I/II trial of the CXCR2 antagonist AZD5069 in combination with enzalutamide (ENZA) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC)
Presenter: Christina Guo
Session: Proffered Paper session: Developmental therapeutics
Resources:
Abstract
Slides
Webcast
Invited Discussant 450O and 454O
Presenter: Chia-Chi Lin
Session: Proffered Paper session: Developmental therapeutics
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session: Developmental therapeutics
Resources:
Webcast